AGA Center for Diagnostics & Therapeutics

Drug development is a complex, time-consuming and expensive process requiring the cooperation of various stakeholders. To help facilitate this process, the AGA Center for Diagnostics and Therapeutics provides objective, independent guidance to companies, regulators, investors and health-care professionals on the development of new therapies and diagnostic tests for digestive disorders.

Expertise and Opportunities

• Identification of Experts and Organization of Expert Meetings

• Clinical Study Design and Endpoint Development

• Development of Educational Programs and Resources

We invite AGA partners to suggest other issues facing the drug and diagnostic industries related to clinical development and regulatory approval.

Resources

i

Meeting Coverage

Read GI & Hepatology News’ coverage of the 2016 AGA Drug Development Conference, which focused on new and emerging drugs for the treatment of GERD, gastroparesis, EoE and dyspepsia.

i

FDA Comment Letter

The AGA Center for Diagnostics and Therapeutics submitted comments on FDA’s 2015 draft guidance document entitled “Gastroparesis: Clinical Evaluation of Drugs for Treatment.”

i

Introduction to the Center

Learn more about why the center was established and its work in the drug and diagnostic space in this AGA Perspectives editorial by Dr. Colin Howden.

i

GERD Treatment Overview

Dr. Colin Howden, chair of the center, discusses the highs and lows of drug development for gastroesophageal reflux disease in a blog post on Applied Clinical Trials.

i

Functional Dyspepsia Trial Design

In this blog post, center board member Dr. Nimish Vakil discusses the need for improved definitions and clinical trials to develop treatment for this common condition.

Latest News

Link Between Antibiotics and IBD Remains Circumstantial

Since inflammatory bowel disease (IBD) is linked to disruption of the intestinal microbiome, antibiotics have come under increasing scrutiny as possible environmental catalysts in IBD – especially if taken in early childhood. So far, the association has been...

read more

Primary Care Providers Can Treat Hep C

Primary care providers can successfully manage direct-acting antiviral (DAA) treatment for hepatitis C, though some complicated cases should still be referred to specialists, experts say. Recent studies have shows that hepatitis C treatment by primary care physicians...

read more

Transform IBD Patient Care, Accelerate IBD Research

2017-07-20 12:59:31 UTC AGA members: Find this interesting? Share your thoughts with colleagues in AGA Community. July 20, 2017 The Crohn’s & Colitis Congress™, combines the strengths of the nation’s leading IBD patient organization,...

read more

Scientific Advisory Board

Colin W. Howden, MD, AGAF, Chair

Colin W. Howden, MD, AGAF, Chair

University of Tennessee Health Science Center, Memphis

Tara A. Altepeter, MD, FDA Liaison*

Food and Drug Administration, Silver Spring, MD

J. Summer Bell III, MD, AGAF

Gastroenterology Ltd., Virginia Beach, VA

Glenn T. Furuta, MD

Children’s Hospital Colorado, Aurora

M. Scott Harris, MD, AGAF

Avaxia Biologics and Georgetown University, Washington, DC

Rajeev Jain, MD, AGAF, Governing Board Liaison

Texas Digestive Disease Consultants, Dallas

Loren Laine, MD, AGAF

Yale University School of Medicine, Fairfield, CT

Gary R. Lichtenstein, MD, AGAF

University of Pennsylvania, Philadelphia

Fred Poordad, MD

University of Texas Health Science Center, San Antonio

Debra G. Silberg, MD, PhD

Shire Pharmaceuticals, Wayne, PA

Nimish B. Vakil, MD, AGAF

University of Wisconsin Medical School, Summit, WI

Teresa L. Wright, MD, AGAF

Genentech, San Francisco, CA

*Denotes non-voting member.

Are you ready to take the next step?

To learn more about the center, please contact Alison Kim, senior director of research and innovation.

Phone Icon

301-654-2055

Pin Icon

4930 Del Ray Ave.
Bethesda, MD 20814

Stay Connected